Blood News and Research

RSS

Study finds significant variability in CPR quality between day and night

CPR quality is worse during in-hospital cardiac arrests occurring overnight than those that happen during the day, according to a new University of Pennsylvania School of Medicine study that will be presented at the American Heart Association's annual Scientific Sessions on November 14.

16 Nov 2010

New high-sensitive blood test may help predict risk of heart failure in older people

Researchers at the University of Maryland School of Medicine in Baltimore report that a new, highly sensitive investigative blood test may help predict the risk of heart failure and cardiovascular death much earlier than previously possible in older people who do not have symptoms of heart failure.

16 Nov 2010

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

A pediatric immunologist at The Children's Hospital of Philadelphia collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder.

16 Nov 2010

Reducing salt intake can enhance health of young adults in future: Research

Cutting back on salt in teenagers' diets by as little as one-half teaspoon, or three grams, a day, could reduce the number of young adults with high blood pressure by 44 to 63 percent, according to new research presented Sunday, Nov. 14 at the American Heart Association's Scientific Sessions 2010 meeting in Chicago.

16 Nov 2010

St. Jude presents results from ASSERT trial for stroke at American Heart Association

St. Jude Medical, Inc., a global medical device company, today announced the results of the ASymptomatic AF and Stroke Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial (ASSERT), a St. Jude Medical sponsored trial conducted by the Population Health Research Institute of McMaster University and Hamilton Health Sciences in Hamilton, Canada.

16 Nov 2010

Research suggests targeting spleen may promote healing of spinal cord injury

The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.

16 Nov 2010

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).

16 Nov 2010

FDA approves Halaven therapy for metastatic late-stage breast cancer

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

16 Nov 2010

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.

16 Nov 2010

Teenage binge drinking could cause mental health problems in adulthood: Study

Binge-drinking teenagers may be putting themselves at higher risk in adulthood for mood disorders such as anxiety and depression, Loyola University Health System researchers report.

16 Nov 2010

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

Beth Israel Deaconess Medical Center (BIDMC) will join the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet), a clinical research network sponsored by the National Heart Lung and Blood Institute (NHLBI) to conduct randomized clinical trials to evaluate new and existing medications for the treatment of idiopathic pulmonary fibrosis (IPF). The network is made up of healthcare institutions from around the United States.

16 Nov 2010

cTnT blood biomarker may predict risk of cardiovascular problems: Study

Certain measures of the blood biomarker cardiac troponin T (cTnT), a cardiac-specific protein, using a highly sensitive test, are associated with the development of heart failure or cardiovascular death in older adults, according to a study that will appear in the December 8 issue of JAMA. The study is being released early online because it will be presented at the American Heart Association's annual meeting.

16 Nov 2010

Oramed presents ORMD-0801 Phase IIb results for Type II diabetes at Annual Meeting in Bethesda

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes.

16 Nov 2010

Sangart's MP4CO receives orphan drug designation for acute pain in sickle cell disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced that its investigational biopharmaceutical product, MP4CO, has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA) for use in treating acute painful sickling crises in patients with sickle cell disease.

15 Nov 2010

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

15 Nov 2010

diaDexus third quarter revenue increases 26% to $3.2 million

diaDexus, Inc., a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced financial results for the third quarter of 2010.

15 Nov 2010

Novel heart attack treatment results presented at premier USA cardiology forum

Regenerative medicine company Mesoblast Limited (ASX:MSB; USADR:MBLTY) has announced that positive preclinical trial results were presented at the American Heart Association’s annual conference in Chicago showing that the company’s proprietary “off-the-shelf” stem cells can be injected simply, safely, and effectively into the coronary arteries after a heart attack to prevent heart failure.

15 Nov 2010

Blood News and Research

Study finds significant variability in CPR quality between day and night

New high-sensitive blood test may help predict risk of heart failure in older people

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

Reducing salt intake can enhance health of young adults in future: Research

St. Jude presents results from ASSERT trial for stroke at American Heart Association

Research suggests targeting spleen may promote healing of spinal cord injury

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

FDA approves Halaven therapy for metastatic late-stage breast cancer

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Teenage binge drinking could cause mental health problems in adulthood: Study

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

cTnT blood biomarker may predict risk of cardiovascular problems: Study

Oramed presents ORMD-0801 Phase IIb results for Type II diabetes at Annual Meeting in Bethesda

Sangart's MP4CO receives orphan drug designation for acute pain in sickle cell disease

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

diaDexus third quarter revenue increases 26% to $3.2 million

Novel heart attack treatment results presented at premier USA cardiology forum

Emerging blood thinners to prevent stroke

BioTime third quarter total revenues increase 82% to $815,284

Unilife and IMCO enter exclusive marketing program for Unitract range of 1mL safety syringes

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News